Bayer acquires rights in Puhe BioPharma cancer drug candidate

Health

Bayer acquires rights in Puhe BioPharma cancer drug candidate

Wed, Mar 26, 2025 0 Comments

Audio By Carbonatix

FRANKFURT (Reuters) -Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with China’s Puhe BioPharma.

Bayer, which did not disclose financial terms, said it had enrolled the first patient to test the drug, a PRMT5 inhibitor that selectively targets MTAP-deleted tumors, in the first phase of clinical trials.

(Reporting by Ludwig Burger, editing by Rachel More)

Previous Hundreds stage Gaza protest against Hamas after conflict resumes

Next Denmark welcomes US decision to skip Greenland dog-sled race amid Trump spat

Salem News Channel | Today

More Health Headlines

Other News to Consider

Follow SRNNews.com

on Facebook

@SRNNews

Subscribe to our Newsletters RSS Feeds

Salem Media, our partners, and affiliates use cookies and similar technologies to enhance your browsing experience, analyze site traffic, personalize site content, and deliver relevant video recommendations. By using this website and continuing to navigate, you consent to our use of such technologies and the sharing of video viewing activity with third-party partners in accordance with the Video Privacy Protection Act and other privacy laws. Privacy Policy

X CLOSE

Email to a Friend

Bayer acquires rights in Puhe BioPharma cancer drug candidate

FRANKFURT (Reuters) -Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with China’s Puhe BioPharma. Bayer, which did not disclose financial terms, said it had enrolled the first patient to test the drug, a PRMT5 inhibitor that selectively targets MTAP-deleted tumors, in the first phase […]

X close